DeusXM
Well-Known Member
- Relationship to Diabetes
- Type 1
Who do you think will be the next manufacturer to make this type of thing ?
I suspect all the big manufacturers have something in their R&D labs and while I'm excited about the Abbott device, I think it's these companies we need to be really watching.
The Libre has been really obviously priced to keep it at the top end of costs that are likely to be paid for by national health care services and in the States, private insurance. The financial argument for the Libre is actually more solid than test strips at the moment because it removes the issue of patient compliance. Docs can be skeptical about unlimited test strips because often they're not convinced people use the information to any real benefit. But if the Libre collates all the information, that can then be given to the care team and it cuts out all the usual "oh, I forgot to test" or "oh, yes, all my reading has been fine" shenanigans doctors often face from patients. It basically removes anecdote from the entire equation. It also partially removes the need for an A1c - who needs a three month average based on an imperfect result when you can see everything.
That means, assuming the Libre performs as it's supposed to (and that's a big assumption), I would be very surprised if it doesn't make it through the NICE approval process.
That's where things get interesting, because it means the mass market for test strips dies in the UK (and likely the US and EU as well), except for the minor calibration/double-check tests. That means if other pharmaceutical companies want to compete, they HAVE to develop their own Libre equivalent. The Libre is what you could probably call a first generation device of its type. It's the first iPhone. As a general rule, the first generation of anything is generally a bit flaky. The second generation one will be a vast improvement, and it'll be the other manufacturers who'll bring the next generation along AND they'll be obliged to price it to compete with the Libre. That means the Libre will then come down in cost and you'll see a price war with the manufacturers. All of this means that by 2020 you'll probably have versions of the Libre that are priced effectively to secure NHS funding and will likely not require calibration. They'll also probably have smaller sensors too.